Evidence map›Paper›PMID 42587106›Full record

ArticleOncogene2026

Targeting the SELP/PSGL1 axis reprograms M2 macrophages and enhances anti-PD-1 efficacy in gastric cancer.

Yue Wu, Xiaobo Peng, Tong Yin, Xiaoxiao Wu, Jingyu Liu, Yulin Xing, Xian Liu, Shuhui Tang, Xiaoxiao Li, Xianbao Zhan

Abstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yue Wu *Department of Oncology, Changhai Hospital, Naval Medical University, Shanghai, China.
Xiaobo Peng *Department of Oncology, Changhai Hospital, Naval Medical University, Shanghai, China.
Tong Yin *Department of Oncology, Changhai Hospital, Naval Medical University, Shanghai, China.
Xiaoxiao WuDepartment of Oncology, Changhai Hospital, Naval Medical University, Shanghai, China.
Jingyu LiuDepartment of Oncology, Changhai Hospital, Naval Medical University, Shanghai, China.
Yulin XingDepartment of Oncology, Changhai Hospital, Naval Medical University, Shanghai, China.
Xian LiuDepartment of Oncology, Changhai Hospital, Naval Medical University, Shanghai, China.
Shuhui TangDepartment of Oncology, Changhai Hospital, Naval Medical University, Shanghai, China.
Xiaoxiao LiDepartment of Oncology, Changhai Hospital, Naval Medical University, Shanghai, China.
Xianbao ZhanDepartment of Oncology, Changhai Hospital, Naval Medical University, Shanghai, China. zhanxianbao@csco.org.cn.ORCID http://orcid.org/0000-0003-3718-466X

Funding

National Natural Science Foundation of China (National Science Foundation of China) 82072707
6 · The paper itself

Abstract

Immune evasion and an immunosuppressive tumor microenvironment contribute to the poor prognosis of gastric cancer (GC), but the mechanisms governing tumor-associated macrophage (TAM) polarization remain unclear. Here we identify P-selectin (SELP) as a key driver of GC progression and immune suppression. SELP was markedly upregulated in GC and correlated with advanced stage, increased M2 macrophage infiltration, and poor survival. Mechanistically, SELP engaged PSGL1 on TAMs to activate PI3K/AKT/mTOR signaling, which enhanced glycolysis and lactate production. Lactate in turn induced MYB, thereby promoting SELP transcription and establishing a feed-forward circuit that sustained M2-like polarization. Therapeutically, genetic or pharmacological targeting of SELP reprogrammed TAMs towards a pro-inflammatory state, increased intratumoural CD8

Indexed as

Immune Checkpoint InhibitorsMacrophagesProgrammed Cell Death 1 ReceptorStomach NeoplasmsTumor-Associated MacrophagesAnimalsCell Line, TumorHumansMicePhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktSignal TransductionTOR Serine-Threonine KinasesTumor MicroenvironmentImmune Checkpoint InhibitorsPhosphatidylinositol 3-KinasesProgrammed Cell Death 1 ReceptorProto-Oncogene Proteins c-aktTOR Serine-Threonine Kinases

Identifiers

PMID42587106

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.